

Name Goar Egoryan, M.D.

A. ACADEMIC HISTORY

Colleges and Universities Attended

June 2016 M.D., *summa cum laude*, Novosibirsk State Medical University, Novosibirsk, Russia

Residency and Fellowship Training

June 2022 – June 2023 PGY3 Chief Resident, Internal Medicine Residency Program, Ascension Saint Francis Hospital, Evanston, IL, USA

June 2020 – June 2023 Internal Medicine Residency Program, Ascension Saint Francis Hospital, Evanston, IL, USA

Sept 2016 – June 2018 Rheumatology Fellowship, Novosibirsk State Medical University, Novosibirsk, Russia

Scholarships, Honors, Awards

2026 Stanford SMART-HM Seed Grant Integrative Medicine for Inpatient Oncology: Faculty Development and Clinical Application

2023 Research Award Internal Medicine Residency, Ascension Saint Francis Hospital, Evanston, IL, USA

2021 Great Catch Award Internal Medicine Residency, Ascension Saint Francis Hospital, Evanston, IL, USA

2020 Intern of the Year Internal Medicine Residency, Ascension Saint Francis Hospital, Evanston, IL, USA

Board Certification

2023-present American Board of Internal Medicine

2019-present ECFMG certificate

Licensure

2023-present California Medical License

2023-present DEA License

2018-2023 Rheumatology License (Russia)

USMLE

USMLE Step 1	268
USMLE Step 2 CK	271
USMLE 2 CS	Pass/first attempt
USMLE Step 3	255

B. EMPLOYMENT

June 2023 – present	Clinical Assistant Professor of Hospital Medicine, Stanford University School of Medicine, Stanford, California
2018-2020	Rheumatology Attending, Private Healthcare Facility RZHD-Meditsina, Novosibirsk, Russia

C. CLINICAL CARE AND TEACHING

Clinical Responsibilities and Appointments

2023-present: Attending hospitalist at Stanford Hospital on oncology med 12 service. 26 weeks per year. Provide comprehensive care to patients with solid tumors admitted with complex, high-acuity conditions, including cancer-related complications, treatment toxicities, infections, malnutrition, and end-of-life care. Make complex clinical decisions and navigate high-stakes situations with patients and families, often integrating input from multiple consulting teams.

2020-2023: Internal medicine residency, trained in community hospital with strong inpatient curriculum and diverse patient population, led many code blues/rapid responses independently without ICU attending/nocturnist in hospital overnight, completed extra ICU rotation during the tenure of residency and placed 20+ central venous catheter and arterial lines.

2018-2020: Rheumatology attending in outpatient clinic, treated patients with a wide variety of autoimmune conditions.

Teaching Experience

2024-2025: Coordinated monthly oncology case conferences for oncology med 12 team, selected speakers, scheduled sessions, arranged logistics including Zoom/room booking.

2022-2023: Taught interns and junior residents through direct supervision, morning reports, noon conferences and dedicated didactic hours as a Chief Resident.

Hospital Committees

2024-2025: Inpatient Oncology Transition of Care Committee, Stanford Hospital

2021-2023: Code Blue/Rapid Response Committee, Ascension Saint Francis Hospital

2021-2023: Antibiotic Stewardship & Infection Control Committee, Ascension Saint Francis Hospital

2021-2023: Research Committee, Ascension Saint Francis Hospital

D. LEADERSHIP EXPERIENCE

2022-2023: PGY3 Chief Resident. Oversaw scheduling and guided 60+ residents, led resident recruitment, coordinated and oversaw resident lectures, consulted with hospital administration and residency program leadership on improving the flow of the residency program.

E. PUBLIC AND PROFESSIONAL SERVICE

Professional Societies

2026-present	Stanford Integrative Medicine Society
2025-present	Society of Hospital Medicine
2022-2023	IDSA
2020-2023	American College of Physicians

F. LANGUAGE PROFICIENCY

Russian	Native
English	Fluent
Armenian	Fluent
Spanish	Beginner

G. ATHLETIC EXPERIENCE

1998-2008	Competitive ballroom dancer
2000-2004	Rhythmic gymnast

H. BIBLIOGRAPHY

1. **Egoryan G**, Zimmet A, Yu M, Pozdol J, Subramanian A, Reddy S, Nelson J. A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene

Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma. Clin Case Rep. 2024 Dec 15;12(12):e9632. doi: 10.1002/ccr3.9632. PMID: 39687659; PMCID: PMC11646813.

2. Rodriguez-Nava G, **Egoryan G**, Goodman KE, Morgan DJ, Salinas JL. Performance of a large language model for identifying central line-associated bloodstream infections (CLABSI) using real clinical notes. *Infection Control & Hospital Epidemiology*. 2025;46(3):305-308. doi:10.1017/ice.2024.164.
3. Rodriguez-Nava G, El Kamari V, Chang H, Egoryan G, Bonilla HF. New-onset sarcoidosis in a patient with long COVID. Clin Case Rep. 2024 Aug 10;12(8):e9186. doi: 10.1002/ccr3.9186. PMID: 39130813; PMCID: PMC11316136.
4. **Egoryan G.**, Rodriguez-Nava G, Response to Vaccination Against COVID-19 in a Community Oncology Practice: a Rational for Antibody Testing, *Open Forum Infectious Diseases*, Volume 10, Issue Supplement_2, December 2023, ofad500.1963, <https://doi.org/10.1093/ofid/ofad500.1963>
5. Meng Q., Rodriguez-Nava G., **Egoryan G.**, 423. Development and Validation of a Predictive Model of New-Onset Deep Vein Thrombosis/Pulmonary Embolism Among Hospitalized COVID-19 Patients: A Retrospective Cohort Study, *Open Forum Infectious Diseases*, Volume 10, Issue Supplement_2, December 2023, ofad500.493, <https://doi.org/10.1093/ofid/ofad500.493>
6. Meng Q., Kishmiryan A., **Egoryan G.**, COVID-19 and the risk of infections caused by multidrug-resistant organisms: a retrospective cohort study in a community hospital. *Chest*. 2023 Oct; 164(4):A798. doi:<https://doi.org/10.1016/j.chest.2023.07.594>
7. **Egoryan G.**, Rodriguez-Nava G., Kishmiryan A., 277. Frequency of Pneumomediastinum and Pneumothorax in COVID-19 Patients: a Retrospective Cohort Study in a Community Hospital in Evanston, Illinois, *Open Forum Infectious Diseases*, Volume 9, Issue Supplement_2, December 2022, ofac492.355, <https://doi.org/10.1093/ofid/ofac492.355>
8. **Egoryan G.**, Rodriguez-Nava G., Kishmiryan A., 2175. Diagnostic Utility of Pneumococcal Urinary Antigen Assay in Clinical Practice: a Retrospective Study in a Community Hospital in Evanston, Illinois, *Open Forum Infectious Diseases*, Volume 9, Issue Supplement_2, December 2022, ofac492.1795, <https://doi.org/10.1093/ofid/ofac492.1795>
9. Rodriguez-Nava G., **Egoryan G.**, Kishmiryan A., 2046. Local validation of methicillin-resistant *Staphylococcus aureus* and *Pseudomonas aeruginosa* prevalence in a community hospital: A cross-sectional retrospective cohort study, *Open Forum Infectious Diseases*, Volume 9, Issue Supplement_2, December 2022, ofac492.1668.

10. Rodriguez-Nava G., **Egoryan G.**, Dong T. et al. Comparison of clinical characteristics and outcomes of hospitalized patients with seasonal coronavirus infection and COVID-19: a retrospective cohort study. *BMC Infect Dis* 22, 618 (2022). <https://doi.org/10.1186/s12879-022-07555-4>
11. **Egoryan G.**, Yanez-Bello M.A., Ginsburg B. et al. Clinical characteristics and outcomes of the first two waves of the COVID-19 pandemic in a community hospital: a retrospective cohort study. *IJID Reg.* 2022 Jun;3:1-7. doi: 10.1016/j.ijregi.2022.02.001. Epub 2022 Feb 6. PMID: 35720147; PMCID: PMC8817945.
12. Saad E., **Egoryan G.**, Padmanabhan S.V. et al. Clostridium tertium Bacteremia: A Marker of an Underlying Perforated Colonic Diverticular Disease in a Non-Neutropenic Patient With COVID-19. *J Med Cases.* 2022 May;13(5):212-218. doi: 10.14740/jmc3916. Epub 2022 Apr 12. PMID: 35655631; PMCID: PMC9119365.
13. Adhikari P., Antala D., **Egoryan G.** et al. A Case of Campylobacter Fetus Subspecies Fetus Systemic Infection. *Cureus.* 2022 Apr 8;14(4):e23963. doi: 10.7759/cureus.23963. PMID: 35541294; PMCID: PMC9080960.
14. Rodriguez-Nava G., **Egoryan G.**, Prasai P., Yanez-Bello M.A., Trelles-Garcia D.P. Characterization of the first 391 reports of myocarditis after mRNA COVID-19 vaccines submitted to the vaccine adverse event reporting system – United States. *Journal of the American College of Cardiology.* 2022 Mar, 79 (9_Supplement) 1839.
15. Saad E., Agab M., **Egoryan G.** et al. Multisystemic Sarcoidosis Presenting with Widespread Vertebral Osseous and Visceral Lesions Masquerading as Metastatic Disease: A Case Report and Literature Review. *Am J Case Rep.* 2022 Feb 7;23:e935158. doi: 10.12659/AJCR.935158. PMID: 35125492; PMCID: PMC8833267.
16. **Egoryan G.**, Chaudry S., Yadav K. et al. Dark urine as the initial manifestation of COVID-19: a case report. *J Med Case Rep.* 2021 Dec 2;15(1):576. doi: 10.1186/s13256-021-03173-x. PMID: 34857045; PMCID: PMC8637504.
17. **Egoryan G.**, Yanez-Bello M.A., Trelles-Garcia D.P. et al. Experience with Remdesivir for the treatment of critical COVID-19 in a community-based hospital in Evanston, Illinois. *Chest.* 2021 Oct;160(4):A542-A543. doi:10.1016/j.chest.2021.07.529.
18. Rodriguez-Nava G., **Egoryan G.**, Trelles-Garcia D.P. et al. The first and second waves of the COVID-19 pandemic in a community hospital ICU. *Chest.* 2021 Oct;160(4):A549–50. DOI: 10.1016/j.chest.2021.07.534.
19. **Egoryan G.**, Hyser E., Mushtaq A.H. et al. Development of cavitory lung disease as a long-

- term complication of coronavirus disease 2019 in a young previously healthy patient: a case report. *J Med Case Rep.* 2021 Jul 13;15(1):377. doi: 10.1186/s13256-021-02961-9. PMID: 34256831; PMCID: PMC8276840.
20. Rodriguez-Nava G., **Egoryan G.**, Trelles-Garcia D.P., Yanez-Bello M.A., Murguia-Fuentes R. Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States. *Ann Allergy Asthma Immunol.* 2021 Jul;127(1):139-140. doi: 10.1016/j.anai.2021.04.004. Epub 2021 Apr 8. PMID: 33838338; PMCID: PMC8026243.
21. Andreev-Drakhlin A., **Egoryan G.**, Shah A.Y. et al. The evolving treatment landscape of advanced urothelial carcinoma. *Curr Opin Oncol.* 2021 May 1;33(3):221-230. doi: 10.1097/CCO.0000000000000722. PMID: 33818541.
22. Rodriguez-Nava G., **Egoryan G.**, Trelles-Garcia D.P., Yanez-Bello M.A., Friedman H., 551. Remdesivir and Tocilizumab for the Treatment of Severe COVID-19 in a Community Hospital: A Retrospective Cohort Study, *Open Forum Infectious Diseases*, Volume 8, Issue Supplement_1, November 2021, Pages S378–S379, <https://doi.org/10.1093/ofid/ofab466.750>
23. **Egoryan G.**, Yanez-Bello M.A., Trelles-Garcia D.P., Friedman H., Rodriguez-Nava G., Experience with Remdesivir for the treatment of critical COVID-19 in a community-based hospital in Evanston, Illinois. *Chest.* 2021 Oct; 160(4):A542-A543.doi:10.1016/j.chest.2021.07.529
24. **Egoryan G.**, Murguia-Fuentes R., Agab M. et al. Posterior reversible encephalopathy syndrome in a patient with Richter's syndrome on combination DA-R-EPOCH chemotherapy regimen: a case report. *J Med Case Rep.* 2021 Apr 12;15(1):161. doi: 10.1186/s13256-021-02780-y. PMID: 33840384; PMCID: PMC8040238.
25. **Egoryan G.**, Dong T., Hyser E., Rodriguez-Nava G., Comparison of respiratory viral coinfection risk between patients hospitalized with COVID-19 and seasonal coronavirus. *Journal of General Internal Medicine* ; 36(SUPPL 1):S145-S146, 2021.
26. Poudel B., Zhang Q., **Egoryan G.** et al. An overlooked cause of septic shock: Staphylococcal Toxic Shock Syndrome secondary to an axillary abscess. *IDCases.* 2020 Dec 31;23:e01039. doi: 10.1016/j.idcr.2020.e01039. PMID: 33473349; PMCID: PMC7803642.
27. Rodriguez-Nava G., Yanez-Bello M.A., **Egoryan G.** et al. A Retrospective Study of Coinfection of SARS-CoV-2 and *Streptococcus pneumoniae* in 11 Hospitalized Patients with Severe COVID-19 Pneumonia at a Single Center. *Med Sci Monit.* 2020 Nov 14;26:e928754.

doi: 10.12659/MSM.928754. PMID: 33188161; PMCID: PMC7673066.

Posters

1. **Egoryan G.** Frequency of Pneumomediastinum and Pneumothorax in COVID-19 Patients: a Retrospective Cohort Study in a Community Hospital in Evanston, Illinois. Poster presented at IDWeek 2022 on October 20, 2022, in Washington DC.
2. **Egoryan G.** Diagnostic Utility of Pneumococcal Urinary Antigen Assay in Clinical Practice: a Retrospective Study in a Community Hospital in Evanston, Illinois. Poster presented at IDWeek 2022 on October 22, 2022, in Washington, DC.
3. **Egoryan G.** Evaluation of the seroconversion rate in response to COVID-19 vaccines among cancer patients: a community- hospital experience. November, 2021. Poster presented at: American College of Physicians Illinois Northern Chapter Resident Poster Competition, IL, USA.
4. **Egoryan G.** Experience with Remdesivir for the treatment of critical COVID-19 in a community-based hospital in Evanston, Illinois. October, 2021. Oral Presentation presented at: CHEST Annual Meeting 2021.
5. **Egoryan G.** Comparison of respiratory viral coinfection risk between patients hospitalized with COVID-19 and seasonal coronavirus. April, 2021. Oral Presentation presented at: 2021 SGIM Annual Meeting

Invited presentations

December 11, 2024 Oncology Case Conference. Stanford Hospital, Stanford, CA

June 5, 2024 “From Rare to Routine: Navigating Immunotherapy Side Effects” Morning Resident Lecture, Ascension Saint Francis Hospital, Evanston, IL